CAMBRIDGE, Mass. — No one seems to quite know who gave Werewolf Therapeutics its name. But it’s very clear where the new startup, founded in 2017 by MPM Capital, got its lab space and its staff: Potenza Therapeutics.

Potenza’s lab space at 1030 Massachusetts Ave. has barely had time to get cold after Japanese drug maker Astellas (ALPMY) acquired the company in December, but the company’s former leadership team is planning to move back in as Werewolf on April 1, the company’s vice president of research and development, Cynthia Seidel-Dugan, told Cambridge regulators on Thursday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy